Standard BioTools Inc. (LAB) Stock Forecast
LAB analyst forecast
as of October 17, 2026- Analyst consensus
- Hold 3.00 / 5 from 1 analysts
- Price target
- $1.35 average of analyst targets
- Upside to target
- +114.3% from the latest close
- Next earnings
- November 3, 2026 EPS estimate $-0.01
- 52-week range
- $0.63 – $1.68
LAB analyst ratings
1 analystsNumber of analysts at each rating.
LAB price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
LAB earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.02 | −$0.02 | −$0.02 | −$0.08 | +75.0% | 1 |
| Current fiscal year (2026) | −$0.10 | −$0.10 | −$0.10 | −$0.20 | +50.0% | 1 |
| Next fiscal year (2027) | −$0.16 | −$0.16 | −$0.16 | −$0.10 | −60.0% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
LAB revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $18.8M | $18.8M | $18.8M | −3.9% | 1 |
| Current fiscal year (2026) | $82.5M | $82.5M | $82.5M | −3.3% | 1 |
| Next fiscal year (2027) | $82.1M | $82.1M | $82.1M | −0.5% | 1 |
LAB EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
LAB revenue: reported and forecast
LAB EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.04 | −$0.04 | −$0.04 | −$0.04 | −$0.02 | −42.9% | 0 up · 0 down |
| Current fiscal year (2026) | −$0.15 | −$0.16 | −$0.16 | −$0.16 | −$0.10 | −35.5% | 0 up · 1 down |
| Next fiscal year (2027) | −$0.14 | −$0.14 | −$0.13 | −$0.14 | −$0.16 | +14.3% | 0 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
LAB earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; LAB beat in 4 of 12.
What analysts expect from LAB
1 analysts cover Standard BioTools; their consensus rating is hold (3.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $1.35, 114.3% above the latest close of $0.63. Analysts expect earnings of −$0.10 per share for 2026, +50.0% from a year earlier. For 2027 the average estimate is −$0.16 per share on revenue of $82.1 million. Standard BioTools beat the EPS estimate in 4 of the last 12 quarters.
Related: LAB income statement, LAB key metrics, LAB chart. See the LAB stock overview for the latest quote and news.
LAB forecast FAQ
What is Standard BioTools's price target?
The average analyst price target for Standard BioTools is $1.35, 114.3% above the latest close of $0.63.
Is Standard BioTools a buy, hold or sell?
Of 1 analysts covering Standard BioTools, 0 rate it a strong buy, 0 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of hold. Ratings are opinions, not a recommendation from Quotelinks.
What is Standard BioTools's EPS forecast?
Analysts forecast −$0.10 per share for 2026 (range −$0.10 to −$0.10); for 2027 the estimate is −$0.16.
What is Standard BioTools's revenue forecast?
The average revenue estimate for 2026 is $82.5 million, growth of −3.3%; for 2027 it is $82.1 million.
When does Standard BioTools report earnings?
Standard BioTools is expected to report results for the quarter ending September 30, 2026 on November 3, 2026 after the market closes; the EPS estimate is $-0.01.
Does Standard BioTools usually beat earnings estimates?
Standard BioTools reported EPS at or above the analyst estimate in 4 of the last 12 quarters.